HematoGenesis™

About MygoGenesis

Founded in 2018 and based in San Diego, MygoGenesis is a private, pre-revenue biotech developing a novel cellular reprogramming platform. Its core technology, the Mygotic Process™, claims to create totipotent cells from a patient's own somatic cells, potentially bypassing challenges associated with iPSCs or embryonic stem cells. The company is pursuing a diversified strategy, aiming to spin out subsidiary companies focused on specific applications like universal blood production, cell banking, and sustainable reagents for endotoxin testing.

Therapeutic Areas